Nigel S Bamford, Nomazulu Dlamini, Bruce H Cohen, Ann Tilton, Scott L Pomeroy, Phillip L Pearl, Nina F Schor, E Steve Roach
{"title":"Not Just Half a Doctor: Promoting Humanism During Stressful Times.","authors":"Nigel S Bamford, Nomazulu Dlamini, Bruce H Cohen, Ann Tilton, Scott L Pomeroy, Phillip L Pearl, Nina F Schor, E Steve Roach","doi":"10.1002/cns3.70053","DOIUrl":"10.1002/cns3.70053","url":null,"abstract":"","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12893704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saumel Ahmadi, Natalie Fulton, Michael Morrissey, Rebekah Landre, Stuart Tomko, Fumihiko Urano, Réjean M Guerriero
Background: Epilepsy with myoclonic and atonic seizures (EMAtS), also known as Doose syndrome, accounts for 1%-2% of childhood epilepsies, and various genes have been implicated in causing this epilepsy syndrome. NUS1 encodes for Nogo-B receptor (NgBR), which stabilizes the dehydrodolichyl-diphosphate synthase complex in the endoplasmic reticulum, promoting its enzymatic activity (cis-IPTase) and thereby regulating cholesterol biosynthesis. Pathogenic variants in NUS1 have been associated with movement disorder and epilepsy; however, the spectrum of epilepsy and electroencephalogram (EEG) phenotype has not been well characterized.
Methods: We describe a single-center case series of five patients with NUS1-related disorder.
Results: In our cohort, three patients met the diagnostic criteria of EMAtS, and the remainder had a milder form of generalized epilepsy. Four patients had a pathogenic variant in NUS1 on one allele, and one patient had a missense change of unclear significance but fit the phenotype of NUS1-related disorder. All patients bearing the pathogenic variants in NUS1 had normal to mild developmental delay at the onset of epilepsy, with normal brain magnetic resonance imaging. Age of seizure onset in these patients was 1-7 years, and patients responded to levetiracetam and/or valproic acid. The EEG findings for these patients included the presence of spike and slow wave discharges, as well as the presence of generalized, invariant monomorphic theta range activity in the awake state, which was seen in four out of the five patients.
Conclusion: Taken together, NUS1 variants are associated with generalized epilepsy phenotype and an invariant EEG pattern of monomorphic theta activity.
{"title":"Epilepsy Phenotypic Spectrum of NUS1-Related Disorder: A Case Series.","authors":"Saumel Ahmadi, Natalie Fulton, Michael Morrissey, Rebekah Landre, Stuart Tomko, Fumihiko Urano, Réjean M Guerriero","doi":"10.1002/cns3.70056","DOIUrl":"10.1002/cns3.70056","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy with myoclonic and atonic seizures (EMAtS), also known as Doose syndrome, accounts for 1%-2% of childhood epilepsies, and various genes have been implicated in causing this epilepsy syndrome. <i>NUS1</i> encodes for Nogo-B receptor (NgBR), which stabilizes the dehydrodolichyl-diphosphate synthase complex in the endoplasmic reticulum, promoting its enzymatic activity (cis-IPTase) and thereby regulating cholesterol biosynthesis. Pathogenic variants in <i>NUS1</i> have been associated with movement disorder and epilepsy; however, the spectrum of epilepsy and electroencephalogram (EEG) phenotype has not been well characterized.</p><p><strong>Methods: </strong>We describe a single-center case series of five patients with <i>NUS1</i>-related disorder.</p><p><strong>Results: </strong>In our cohort, three patients met the diagnostic criteria of EMAtS, and the remainder had a milder form of generalized epilepsy. Four patients had a pathogenic variant in <i>NUS1</i> on one allele, and one patient had a missense change of unclear significance but fit the phenotype of <i>NUS1</i>-related disorder. All patients bearing the pathogenic variants in <i>NUS1</i> had normal to mild developmental delay at the onset of epilepsy, with normal brain magnetic resonance imaging. Age of seizure onset in these patients was 1-7 years, and patients responded to levetiracetam and/or valproic acid. The EEG findings for these patients included the presence of spike and slow wave discharges, as well as the presence of generalized, invariant monomorphic theta range activity in the awake state, which was seen in four out of the five patients.</p><p><strong>Conclusion: </strong>Taken together, <i>NUS1</i> variants are associated with generalized epilepsy phenotype and an invariant EEG pattern of monomorphic theta activity.</p>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12914875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146229673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katharine E. Joslyn, Ashley N. Eisenberg, Veronica M. Lee, Linda Rozell-Shannon, Anne M. Comi
Diagnosis and treatment of Sturge–Weber syndrome (SWS) brain involvement in infants born with a port-wine birthmark who are at risk of seizures requires close neurological monitoring [1, 2]. In 90% of patients with SWS brain involvement, seizures will occur before 2 years of age [2]. Early seizures in patients with SWS are typically focal or partial, prolonged, and often associated with tachycardia. Less commonly, they may present with bradycardia and desaturations, which are often not detectable on seizure-specific devices [3]. There has been a notable increase in parents using infant monitoring devices (IMDs) in the Hunter Nelson Sturge–Weber Center. The present study analyzed parental experience using commercially available IMDs and assessed whether these devices may be useful for detecting clinically diagnosed seizures in patients with SWS.
We sent a clinical questionnaire developed in Qualtrics via a secure email link to parents of patients < 5 y of age diagnosed or at risk for SWS and seen between August 31, 2021, and August 31, 2024 (N = 118) at Kennedy Krieger (KK). Twenty-two research-consented patients responded to the questionnaire. We shared the questionnaire with the Vascular Birthmarks Foundation (VBF), who posted it on SurveyMonkey on Facebook pages between February 7, 2025, and April 21, 2025 (N = 37 respondents). See Figures S1a,b for questionnaire and Tables S1a–S2b for demographic information and SWS characteristics.
While the data from the clinical site came from a closely followed patient population, the data from the advocacy site came from participants without a well-characterized clinical presentation. In addition, it is not certain whether the two groups could have generated multiple responses from the same individuals. Each site yielded the same conclusions, supporting broader generalization.
Parents reported having an overall positive experience using an IMD. See Figure S4 for the combined parental Likert scale data. This initial study supports the use of IMDs to aid in decreasing anxiety in parents of infants with SWS brain involvement and epilepsy, and the need for future research, including larger and more diverse sample sizes and retrospective and prospective studies, to determine if the use of IMDs in these patients can detect epileptic seizures.
Katharine E. Joslyn: writing – original draft, writing–review and editing, data visualization. Ashley N. Eisenberg and Veronica M. Lee: data curation, writing–review and editing. Linda Rozell-Shannon: conceptualization, data curation, writing–review and editing. Anne M. Comi: conceptualization, supervision, writing–review and editing.
A.M.C. is an editorial board member of ACNS. The other authors declare no conflicts of interest.
{"title":"Infant Monitoring Devices in Infants With or at Risk for Sturge–Weber Syndrome: Analysis of Clinical Questionnaire Supports Reduced Parent Anxiety","authors":"Katharine E. Joslyn, Ashley N. Eisenberg, Veronica M. Lee, Linda Rozell-Shannon, Anne M. Comi","doi":"10.1002/cns3.70046","DOIUrl":"https://doi.org/10.1002/cns3.70046","url":null,"abstract":"<p>Diagnosis and treatment of Sturge–Weber syndrome (SWS) brain involvement in infants born with a port-wine birthmark who are at risk of seizures requires close neurological monitoring [<span>1, 2</span>]. In 90% of patients with SWS brain involvement, seizures will occur before 2 years of age [<span>2</span>]. Early seizures in patients with SWS are typically focal or partial, prolonged, and often associated with tachycardia. Less commonly, they may present with bradycardia and desaturations, which are often not detectable on seizure-specific devices [<span>3</span>]. There has been a notable increase in parents using infant monitoring devices (IMDs) in the Hunter Nelson Sturge–Weber Center. The present study analyzed parental experience using commercially available IMDs and assessed whether these devices may be useful for detecting clinically diagnosed seizures in patients with SWS.</p><p>We sent a clinical questionnaire developed in Qualtrics via a secure email link to parents of patients < 5 y of age diagnosed or at risk for SWS and seen between August 31, 2021, and August 31, 2024 (<i>N</i> = 118) at Kennedy Krieger (KK). Twenty-two research-consented patients responded to the questionnaire. We shared the questionnaire with the Vascular Birthmarks Foundation (VBF), who posted it on SurveyMonkey on Facebook pages between February 7, 2025, and April 21, 2025 (<i>N</i> = 37 respondents). See Figures S1a,b for questionnaire and Tables S1a–S2b for demographic information and SWS characteristics.</p><p>While the data from the clinical site came from a closely followed patient population, the data from the advocacy site came from participants without a well-characterized clinical presentation. In addition, it is not certain whether the two groups could have generated multiple responses from the same individuals. Each site yielded the same conclusions, supporting broader generalization.</p><p>Parents reported having an overall positive experience using an IMD. See Figure S4 for the combined parental Likert scale data. This initial study supports the use of IMDs to aid in decreasing anxiety in parents of infants with SWS brain involvement and epilepsy, and the need for future research, including larger and more diverse sample sizes and retrospective and prospective studies, to determine if the use of IMDs in these patients can detect epileptic seizures.</p><p><b>Katharine E. Joslyn:</b> writing – original draft, writing–review and editing, data visualization. <b>Ashley N. Eisenberg and Veronica M. Lee:</b> data curation, writing–review and editing. <b>Linda Rozell-Shannon:</b> conceptualization, data curation, writing–review and editing. <b>Anne M. Comi:</b> conceptualization, supervision, writing–review and editing.</p><p>A.M.C. is an editorial board member of ACNS. The other authors declare no conflicts of interest.</p>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"326-329"},"PeriodicalIF":0.0,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xingyu Chen, Shuhei Tomoshige, Ria Wright, Vera J. Burton, Gwendolyn Gerner, Nathanael Kuo, Jill S. Chotiyanonta, Raul Chavez-Valdez, Ernest M. Graham, Frances J. Northington, Kenichi Oishi
Objective
Accurate prediction of both favorable and unfavorable long-term neurodevelopmental outcomes of neonatal hypoxic-ischemic encephalopathy (HIE) is essential for clinical care, yet the brain structures underlying a favorable prognosis remain unclear. This study aimed to identify diffusion magnetic resonance imaging (MRI) measures that can predict the 2-year outcomes in neonates with HIE.
Methods
We analyzed whole-brain diffusion MRI scans from a retrospective cohort of 40 neonates with HIE, acquired within 14 days of birth. Diffusion measures were quantified across 16 cerebrum regions covering the whole cerebrum. We used the area under the Receiver Operating Characteristic curve (AUC) to evaluate the performance of regional fractional anisotropy (FA) and mean diffusivity (MD) values in predicting neurodevelopmental outcomes assessed at 2 years of age.
Results
Reduced FA in the thalamus (AUC = 0.990), basal ganglia (AUC = 0.961), basal forebrain (AUC = 0.951), and limbic white matter (AUC = 0.961) strongly predicted severe disability or death, whereas preserved limbic white matter FA uniquely predicted favorable outcomes (AUC = 0.811).
Conclusion
While FA reduction in the thalamus, basal ganglia, and basal forebrain is a robust marker for severe outcomes, the limbic white matter demonstrated sensitivity to mild hypoxic-ischemic injury. Therefore, the preservation can be a potential marker for predicting favorable neurodevelopmental trajectories.
{"title":"Preserved Limbic White Matter Predicts Favorable 2-Year Outcomes in Neonatal Hypoxic-Ischemic Encephalopathy","authors":"Xingyu Chen, Shuhei Tomoshige, Ria Wright, Vera J. Burton, Gwendolyn Gerner, Nathanael Kuo, Jill S. Chotiyanonta, Raul Chavez-Valdez, Ernest M. Graham, Frances J. Northington, Kenichi Oishi","doi":"10.1002/cns3.70047","DOIUrl":"https://doi.org/10.1002/cns3.70047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Accurate prediction of both favorable and unfavorable long-term neurodevelopmental outcomes of neonatal hypoxic-ischemic encephalopathy (HIE) is essential for clinical care, yet the brain structures underlying a favorable prognosis remain unclear. This study aimed to identify diffusion magnetic resonance imaging (MRI) measures that can predict the 2-year outcomes in neonates with HIE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed whole-brain diffusion MRI scans from a retrospective cohort of 40 neonates with HIE, acquired within 14 days of birth. Diffusion measures were quantified across 16 cerebrum regions covering the whole cerebrum. We used the area under the Receiver Operating Characteristic curve (AUC) to evaluate the performance of regional fractional anisotropy (FA) and mean diffusivity (MD) values in predicting neurodevelopmental outcomes assessed at 2 years of age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Reduced FA in the thalamus (AUC = 0.990), basal ganglia (AUC = 0.961), basal forebrain (AUC = 0.951), and limbic white matter (AUC = 0.961) strongly predicted severe disability or death, whereas preserved limbic white matter FA uniquely predicted favorable outcomes (AUC = 0.811).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While FA reduction in the thalamus, basal ganglia, and basal forebrain is a robust marker for severe outcomes, the limbic white matter demonstrated sensitivity to mild hypoxic-ischemic injury. Therefore, the preservation can be a potential marker for predicting favorable neurodevelopmental trajectories.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"308-313"},"PeriodicalIF":0.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chelsey F. Stillman, Mona P. Jacobson, Jill M. Marks, Craig A. Press, Kelly G. Knupp, Kevin C. Ess
Introduction
A worldwide shortage of pediatric neurologists, combined with increased demand, increased wait times, and clinician burnout, have led to substantial access limitations. Given these challenges, we need to ensure advanced practice providers (APPs) in pediatric neurology are utilized effectively. Our results provide a framework for optimizing modern pediatric neurology practice through a thoughtful consideration of APP integration.
Methods
A survey was sent through two large neurology academic organizations. Emails were also sent to known professional contacts across 59 practice sites. An electronic survey in REDCap with 31 open-ended or multiple-choice questions about demographics, supervision, inpatient and outpatient clinical processes, procedures, and scholarly activities was sent.
Results
Surveys were completed from 29 sites. Sixteen of these sites (55%) reported APPs do not have demographic restrictions in their outpatient practice. At many practice sites APPs perform inpatient consultations, with variable models for independence and partnership with attending neurologists. APPs subspecialize frequently and perform a variety of procedures including lumbar punctures and headache treatment injections.
Conclusion
Most US-based APPs in outpatient pediatric neurology practice autonomously and also frequently perform procedures. APP independence in the inpatient setting should be expanded. As pediatric neurology practices evolve, information regarding the landscape of APP clinical responsibilities will aid in increasing access to care.
{"title":"Landscape of Advanced Practice Provider Responsibilities in Pediatric Neurology","authors":"Chelsey F. Stillman, Mona P. Jacobson, Jill M. Marks, Craig A. Press, Kelly G. Knupp, Kevin C. Ess","doi":"10.1002/cns3.70041","DOIUrl":"https://doi.org/10.1002/cns3.70041","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A worldwide shortage of pediatric neurologists, combined with increased demand, increased wait times, and clinician burnout, have led to substantial access limitations. Given these challenges, we need to ensure advanced practice providers (APPs) in pediatric neurology are utilized effectively. Our results provide a framework for optimizing modern pediatric neurology practice through a thoughtful consideration of APP integration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A survey was sent through two large neurology academic organizations. Emails were also sent to known professional contacts across 59 practice sites. An electronic survey in REDCap with 31 open-ended or multiple-choice questions about demographics, supervision, inpatient and outpatient clinical processes, procedures, and scholarly activities was sent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Surveys were completed from 29 sites. Sixteen of these sites (55%) reported APPs do not have demographic restrictions in their outpatient practice. At many practice sites APPs perform inpatient consultations, with variable models for independence and partnership with attending neurologists. APPs subspecialize frequently and perform a variety of procedures including lumbar punctures and headache treatment injections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Most US-based APPs in outpatient pediatric neurology practice autonomously and also frequently perform procedures. APP independence in the inpatient setting should be expanded. As pediatric neurology practices evolve, information regarding the landscape of APP clinical responsibilities will aid in increasing access to care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"292-298"},"PeriodicalIF":0.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shital H. Patel, Eleni Panagiotakaki, Beiyu Liu, Carmen Fons, Lyndsey Prange, Maria T. Papadopoulou, April Boggs, Elisa De Grandis, Aikaterini Vezyroglou, Francesco Fortunato, Simona Balestrini, Francesca Ragona, Eugenia Julia Tosi, Claudio Zucca, Giacomo Garone, Andrey Megvinov, Giosuè Lo Bosco, Michela Stagnaro, Julie Uchitel, Marion Comajuan, Matthildi Athina Papathanasiou Terzi, Jennifer Anticona, Joan M. Jasien, Jeffrey Wuchich, Sigurdur H. Johannesson, J. Narayan, J. Helen Cross, Sanjay M. Sisodiya, Hwanhee Hong, Alexis Arzimanoglou, Rosaria Vavassori, Mohamad A. Mikati
Objective
The natural history of the most common ATP1A3-related disease, alternating hemiplegia of childhood (AHC), has not been determined. We investigated three hypotheses: (1) AHC worsens over time; (2) several novel factors correlate with long-term outcomes; and (3) AHC manifests high mortality.
Methods
In a large cross-sectional study with a nested period of prospective 1–3-year follow-up, 115 patients (0.3–46.0 years old, 9 centers/5 countries) were evaluated using across-center-standardized protocol and validated scales. Univariable and multivariable linear-mixed-effects models with random intercepts and random slopes for age, adjusted for confounding variables, allowed for the determination of the effect of age throughout the total age range of patients studied.
Results
Course: We identified a distinction between two periods, namely the period of early childhood (age 1–5 years) and the period of later childhood to mid-adulthood. Intellectual and non-paroxysmal disability indexes (IDS, NPDI) scores as well as the Vineland Adaptive Behavior Composite and its subscales worsened during early childhood, but not in the period after that. The extent of motor skills impairment did not differ with age in either period. Within the PDI (paroxysmal disability index) scores, dystonia severity scores did not differ with age in either period; however, plegia severity scores did improve with age after 5 years of age. Prognostic variables included the following: (1) Epilepsy was associated with worse NPDI, intellectual, and fine and gross motor skills. (2) Worse early life PDI and NPDI scores were significantly associated with worse respective scores at the latest follow-up. (3) Worse early life NPDI scores were also associated with worse IDS and fine and gross motor scores at the latest follow-up. (4) D801N mutation was associated with worse PDI. (4) E815K mutation was associated with worse IDS. Mortality was 1.12 deaths/100 patient-years and 6.5 sudden unexpected death in epilepsy (SUDEP) deaths/1000 patient-years.
Interpretation
AHC is a progressive disease, and early childhood is the vulnerable period. We identified several novel prognostic indicators and a mortality rate, which provide critical information not only regarding prognostication, counseling, and underlying pathophysiology but also for planning therapeutic studies.
{"title":"Natural History of Alternating Hemiplegia of Childhood: Vulnerabilities in Early Childhood and Predictive Factors for Long-Term Outcomes","authors":"Shital H. Patel, Eleni Panagiotakaki, Beiyu Liu, Carmen Fons, Lyndsey Prange, Maria T. Papadopoulou, April Boggs, Elisa De Grandis, Aikaterini Vezyroglou, Francesco Fortunato, Simona Balestrini, Francesca Ragona, Eugenia Julia Tosi, Claudio Zucca, Giacomo Garone, Andrey Megvinov, Giosuè Lo Bosco, Michela Stagnaro, Julie Uchitel, Marion Comajuan, Matthildi Athina Papathanasiou Terzi, Jennifer Anticona, Joan M. Jasien, Jeffrey Wuchich, Sigurdur H. Johannesson, J. Narayan, J. Helen Cross, Sanjay M. Sisodiya, Hwanhee Hong, Alexis Arzimanoglou, Rosaria Vavassori, Mohamad A. Mikati","doi":"10.1002/cns3.70037","DOIUrl":"https://doi.org/10.1002/cns3.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The natural history of the most common <i>ATP1A3</i>-related disease, alternating hemiplegia of childhood (AHC), has not been determined. We investigated three hypotheses: (1) AHC worsens over time; (2) several novel factors correlate with long-term outcomes; and (3) AHC manifests high mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a large cross-sectional study with a nested period of prospective 1–3-year follow-up, 115 patients (0.3–46.0 years old, 9 centers/5 countries) were evaluated using across-center-standardized protocol and validated scales. Univariable and multivariable linear-mixed-effects models with random intercepts and random slopes for age, adjusted for confounding variables, allowed for the determination of the effect of age throughout the total age range of patients studied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><b>Course:</b> We identified a distinction between two periods, namely the period of early childhood (age 1–5 years) and the period of later childhood to mid-adulthood. Intellectual and non-paroxysmal disability indexes (IDS, NPDI) scores as well as the Vineland Adaptive Behavior Composite and its subscales worsened during early childhood, but not in the period after that. The extent of motor skills impairment did not differ with age in either period. Within the PDI (paroxysmal disability index) scores, dystonia severity scores did not differ with age in either period; however, plegia severity scores did improve with age after 5 years of age. <b>Prognostic variables</b> included the following: (1) Epilepsy was associated with worse NPDI, intellectual, and fine and gross motor skills. (2) Worse early life PDI and NPDI scores were significantly associated with worse respective scores at the latest follow-up. (3) Worse early life NPDI scores were also associated with worse IDS and fine and gross motor scores at the latest follow-up. (4) <i>D801N</i> mutation was associated with worse PDI. (4) <i>E815K</i> mutation was associated with worse IDS. <b>Mortality was</b> 1.12 deaths/100 patient-years and 6.5 sudden unexpected death in epilepsy (SUDEP) deaths/1000 patient-years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>AHC is a progressive disease, and early childhood is the vulnerable period. We identified several novel prognostic indicators and a mortality rate, which provide critical information not only regarding prognostication, counseling, and underlying pathophysiology but also for planning therapeutic studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"260-273"},"PeriodicalIF":0.0,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michaela Squire, Jenna K. Lea, Zheng (Jane) Fan, Senyene E. Hunter
Background
Pathogenic CYFIP2 variants cause developmental and epileptic encephalopathy (DEE), characterized by early-onset intractable epilepsy and developmental delay. The disease course has not been delineated. Codon Arg87 is a de novo mutational hotspot associated with a severe DEE phenotype via gain-of-function mechanisms. Currently, there are no targeted therapies for CYFIP2-related DEE. Genetic therapies initiated at early symptomatic stages have demonstrated benefit in other disorders and may be an important consideration for this patient population.
Methods
We describe a child with a de novo CYFIP2 Arg87Cys variant and a unique clinical course, along with a comprehensive literature review of reported cases. We identified 41 additional patients with pathogenic or likely pathogenic CYFIP2 variants.
Results
The Arg87Cys variant was present in 12/42 (29%) patients. An additional 27 variants are described across 30 patients. All individuals had global developmental delay, 32/42 (76%) developed epilepsy, and 25/42 (60%) experienced seizure onset in the first year of life. Of those with seizures, 16/32 (50%) had epileptic spasms, and 5/32 (16%), including our patient, developed other seizure types before epileptic spasm onset. Interestingly, our patient is the only report of developmental and electroencephalographic (EEG) normalization after initial seizure onset and before spasms.
Conclusions
Our patient expands the phenotype of CYFIP2-related DEE by demonstrating developmental and EEG normalization after seizure onset and before onset of epileptic spasms and global developmental delay. Given the growing field of genetic therapies and other precision medicines, this period of normalization may represent a window of opportunity for future early intervention.
{"title":"Expanding the Phenotype of CYFIP2-Related Developmental Epileptic Encephalopathy: Case Report and Literature Review","authors":"Michaela Squire, Jenna K. Lea, Zheng (Jane) Fan, Senyene E. Hunter","doi":"10.1002/cns3.70036","DOIUrl":"https://doi.org/10.1002/cns3.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pathogenic <i>CYFIP2</i> variants cause developmental and epileptic encephalopathy (DEE), characterized by early-onset intractable epilepsy and developmental delay. The disease course has not been delineated. Codon Arg87 is a de novo mutational hotspot associated with a severe DEE phenotype via gain-of-function mechanisms. Currently, there are no targeted therapies for <i>CYFIP2</i>-related DEE. Genetic therapies initiated at early symptomatic stages have demonstrated benefit in other disorders and may be an important consideration for this patient population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We describe a child with a de novo <i>CYFIP2</i> Arg87Cys variant and a unique clinical course, along with a comprehensive literature review of reported cases. We identified 41 additional patients with pathogenic or likely pathogenic <i>CYFIP2</i> variants.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The Arg87Cys variant was present in 12/42 (29%) patients. An additional 27 variants are described across 30 patients. All individuals had global developmental delay, 32/42 (76%) developed epilepsy, and 25/42 (60%) experienced seizure onset in the first year of life. Of those with seizures, 16/32 (50%) had epileptic spasms, and 5/32 (16%), including our patient, developed other seizure types before epileptic spasm onset. Interestingly, our patient is the only report of developmental and electroencephalographic (EEG) normalization after initial seizure onset and before spasms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our patient expands the phenotype of <i>CYFIP2</i>-related DEE by demonstrating developmental and EEG normalization after seizure onset and before onset of epileptic spasms and global developmental delay. Given the growing field of genetic therapies and other precision medicines, this period of normalization may represent a window of opportunity for future early intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"314-323"},"PeriodicalIF":0.0,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div> <section> <h3> Background and Objectives</h3> <p>Children with autism spectrum disorder (ASD) often experience challenges integrating visual information to guide motor behavior, particularly in dynamic (speeded) contexts. We investigated the effects of varying stimulus tracking speed on visual-motor integration (VMI), addressing our hypothesis that ASD diagnosis and symptom severity would be associated with impaired performance on dynamic, speeded (vs. slow/static) VMI.</p> </section> <section> <h3> Methods</h3> <p>Fifty-four children aged 8–12 years (ASD: <i>n</i> = 16; typically developing [TD] controls: <i>n</i> = 38) successfully completed a continuous grip-force tracking task involving three conditions: static, slow, and fast visual trajectories. A linear mixed-effects model was used to examine the effects of ASD (vs. TD) diagnosis on speeded VMI. We further examined the correlation between speeded VMI and both clinician-rated (Autism Diagnostic Observation Schedule, Second Edition [ADOS-2]) and parent-reported Social Responsiveness Scales, Second Edition (SRS-2) autism symptoms.</p> </section> <section> <h3> Results</h3> <p>A significant interaction between diagnosis and condition was observed (<i>p</i> = 0.03), indicating that group differences in tracking accuracy varied by stimulus speed. Children with ASD showed significantly greater tracking error than TD peers in the fast condition (ASD: 13.5 ± 1.0 [95% CI: 11.3–15.7]; TD: 10.5 ± 0.7 [95% CI: 9.1–12.0]; <i>p</i> = 0.02), but not in the static (<i>p</i> = 0.80) or slow (<i>p</i> = 0.55) conditions. Both groups showed increased error as speed increased, but the ASD group showed greater impairment under speeded conditions. Higher ADOS-2 Total scores predicted greater error in the fast versus slow (<i>p</i> = 0.009) and fast versus static (<i>p</i> = 0.06) contrasts and in the fast condition alone (<i>p</i> = 0.02). Elevated SRS-2 Total scores were similarly associated with greater error in the fast versus slow (<i>p</i> = 0.02) and fast versus static (<i>p</i> = 0.02) comparisons, though not in the fast condition alone (<i>p</i> = 0.23).</p> </section> <section> <h3> Discussion</h3> <p>The findings support difficulty with speeded dynamic VMI as a scalable autism biomarker. Further development of these biomarkers could be helpful to guiding behavioral interventions, for instance, identifying children who would best respond to slowing visual cues during therapy. Future studies should refine assessment tools to extend assessments of dynamic VMI to younger and more affected children and
{"title":"Speed-Dependent Visual-Motor Tracking Differences in Children With Autism Relate to Core Symptoms","authors":"Daniel E. Lidstone, Stewart H. Mostofsky","doi":"10.1002/cns3.70043","DOIUrl":"https://doi.org/10.1002/cns3.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Children with autism spectrum disorder (ASD) often experience challenges integrating visual information to guide motor behavior, particularly in dynamic (speeded) contexts. We investigated the effects of varying stimulus tracking speed on visual-motor integration (VMI), addressing our hypothesis that ASD diagnosis and symptom severity would be associated with impaired performance on dynamic, speeded (vs. slow/static) VMI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-four children aged 8–12 years (ASD: <i>n</i> = 16; typically developing [TD] controls: <i>n</i> = 38) successfully completed a continuous grip-force tracking task involving three conditions: static, slow, and fast visual trajectories. A linear mixed-effects model was used to examine the effects of ASD (vs. TD) diagnosis on speeded VMI. We further examined the correlation between speeded VMI and both clinician-rated (Autism Diagnostic Observation Schedule, Second Edition [ADOS-2]) and parent-reported Social Responsiveness Scales, Second Edition (SRS-2) autism symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significant interaction between diagnosis and condition was observed (<i>p</i> = 0.03), indicating that group differences in tracking accuracy varied by stimulus speed. Children with ASD showed significantly greater tracking error than TD peers in the fast condition (ASD: 13.5 ± 1.0 [95% CI: 11.3–15.7]; TD: 10.5 ± 0.7 [95% CI: 9.1–12.0]; <i>p</i> = 0.02), but not in the static (<i>p</i> = 0.80) or slow (<i>p</i> = 0.55) conditions. Both groups showed increased error as speed increased, but the ASD group showed greater impairment under speeded conditions. Higher ADOS-2 Total scores predicted greater error in the fast versus slow (<i>p</i> = 0.009) and fast versus static (<i>p</i> = 0.06) contrasts and in the fast condition alone (<i>p</i> = 0.02). Elevated SRS-2 Total scores were similarly associated with greater error in the fast versus slow (<i>p</i> = 0.02) and fast versus static (<i>p</i> = 0.02) comparisons, though not in the fast condition alone (<i>p</i> = 0.23).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>The findings support difficulty with speeded dynamic VMI as a scalable autism biomarker. Further development of these biomarkers could be helpful to guiding behavioral interventions, for instance, identifying children who would best respond to slowing visual cues during therapy. Future studies should refine assessment tools to extend assessments of dynamic VMI to younger and more affected children and ","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"274-281"},"PeriodicalIF":0.0,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Biotin is an essential cofactor for four carboxylase enzymes that participate in glucose, amino acid, and fatty acid catabolism [<span>1</span>]. Biotin recycling is essential since humans cannot synthesize this molecule <i>de novo</i>, and it is mediated by the enzyme biotinidase. Deficiency of this enzyme leads to the disturbance of metabolic homeostasis with clinical features including seizures, ataxia, hypotonia, developmental delay, eczema, alopecia, and occasional ophthalmologic and auditory symptoms [<span>2</span>]. Biotinidase deficiency (BD) is an autosomal recessive disorder. Mild BD refers to the form of the disease with 10%–30% of enzyme activity, and these patients can be asymptomatic until triggered by metabolic stress [<span>2</span>]. We describe a teenager with well-controlled generalized epilepsy who was eventually diagnosed with mild BD.</p><p>This 14-year-old previously healthy girl was diagnosed with idiopathic generalized epilepsy. She had normal development and was noted to be intellectually gifted. She was socially appropriate and participated in competitive cheerleading at school. Her physical examination was normal, including symmetric reflexes in the extremities and a thorough motor and sensory examination. Electroencephalogram indicated generalized, posterior-predominant epileptiform discharges. As part of her epilepsy evaluation, magnetic resonance imaging (MRI) of the brain showed a hyperintense T2-weighted signal in the right cerebral peduncle (Figure 1a) with no abnormal postcontrast enhancement on FLAIR (fluid-attenuated inversion recovery). Whole-exome sequence revealed compound heterozygosity for two pathogenic variants in the <i>BTD</i> gene, confirming a diagnosis of BD.</p><p>Her regimen included levetiracetam 750 mg twice daily and biotin 5 mg daily. MRI brain at 8 months after initial scan showed interval decrease in signal intensity and size of the right cerebral peduncle lesion (Figure 1b). At 20 months after initial imaging, the lesion was barely detectable on imaging (Figure 1c). No further seizure episodes were observed, although the relationship to her epilepsy is unknown. We are currently evaluating when to stop her antiseizure medication.</p><p>This report showcases a rare but treatable cause for epilepsy. The vast majority of BD occurs in the first few months of life and usually before 5 years of age [<span>3</span>]. When the deficiency presents late, it most commonly involves the central nervous system and can mimic acquired neuroinflammatory disorders [<span>2, 3</span>]. In one study, neurological problems occurred in 31% of adult-onset BD and 43% of mild BD, with seizures being one of the most frequent symptoms [<span>2</span>]. While MRI of the brain and spinal cord can be normal, both white matter lesions within the brain and spinal cord have been reported. In one study, the most common imaging abnormalities in children with BD included the optic pathway, fornices, mamillary bodies, hipp
生物素是参与葡萄糖、氨基酸和脂肪酸分解代谢的四种羧化酶必不可少的辅助因子。生物素回收是必不可少的，因为人类不能从头合成这种分子，它是由生物素酶介导的。缺乏这种酶可导致代谢稳态紊乱，其临床特征包括癫痫发作、共济失调、张力低下、发育迟缓、湿疹、脱发以及偶尔的眼科和听觉症状[2]。生物素酶缺乏症是一种常染色体隐性遗传病。轻度双相障碍是指酶活性为10%-30%的疾病形式，这些患者在代谢应激[2]触发前可无症状。我们描述了一个控制良好的全身性癫痫的青少年，最终被诊断为轻度bd。这个14岁的健康女孩被诊断为特发性全身性癫痫。她发育正常，被认为有智力天赋。她在社交上很得体，在学校参加了拉拉队比赛。她的体格检查正常，包括四肢对称反射和彻底的运动和感觉检查。脑电图显示全身性，后显性癫痫样放电。作为癫痫评估的一部分，脑部磁共振成像（MRI）显示右脑脑蒂有高强度的t2加权信号（图1a）， FLAIR（液体衰减反转恢复）未见异常增强。全外显子组序列显示BTD基因的两种致病变异呈复合杂合性，确认诊断为BTD。她的治疗方案包括左乙曲西坦750 mg，每日2次，生物素5 mg，每日2次。初次扫描后8个月的脑MRI显示右脑脑蒂病变信号强度和大小间隔性下降（图1b）。在首次影像学检查后20个月，病变在影像学上几乎无法检测到（图1c）。没有观察到进一步的癫痫发作，尽管与癫痫的关系尚不清楚。我们正在评估何时停止她的抗癫痫药物治疗。本报告展示了一种罕见但可治疗的癫痫病因。绝大多数双相障碍发生在生命的最初几个月，通常在5岁之前。当缺乏症出现较晚时，它最常累及中枢神经系统，并可模仿获得性神经炎性疾病[2,3]。在一项研究中，31%的成人双相障碍患者和43%的轻度双相障碍患者出现神经系统问题，其中癫痫发作是最常见的症状之一。虽然大脑和脊髓的MRI可以正常，但大脑和脊髓内的白质病变都有报道。在一项研究中，BD患儿最常见的影像学异常包括视神经通路、穹窿、乳状体、海马、脑干和脊髓[4]。对于伴有不明原因白质病变的广泛性癫痫患者，我们鼓励考虑进行BTD基因的基因检测，因为新生儿筛查仅捕获略多于一半（51.5%）的患有这种疾病的婴儿，并且由于其显著的残留酶活性[2]，轻度缺陷可能会被遗漏。正如我们的病人所证明的那样，治疗可以逆转已发现的病变并防止进一步的并发症。我们描述了一个具有非典型BD临床表现的儿科患者，以及在全面性癫痫和不明原因的MRI白质病变的鉴别诊断中考虑这种疾病的重要性。临床医生应该保持警惕，因为通过基因检测和及时启动生物素的早期识别可以导致显著的临床和放射学改善。赖淑梅：写作-原稿，写作-审查和编辑，资源，数据管理，调查，验证。Fernando N. Galan：概念化，监督，调查，写作-审查和编辑，验证。作者声明无利益冲突。
{"title":"A Rare and Treatable Cause for Generalized Epilepsy: Biotinidase Deficiency","authors":"Sammie Lai, Fernando N. Galan","doi":"10.1002/cns3.70042","DOIUrl":"https://doi.org/10.1002/cns3.70042","url":null,"abstract":"<p>Biotin is an essential cofactor for four carboxylase enzymes that participate in glucose, amino acid, and fatty acid catabolism [<span>1</span>]. Biotin recycling is essential since humans cannot synthesize this molecule <i>de novo</i>, and it is mediated by the enzyme biotinidase. Deficiency of this enzyme leads to the disturbance of metabolic homeostasis with clinical features including seizures, ataxia, hypotonia, developmental delay, eczema, alopecia, and occasional ophthalmologic and auditory symptoms [<span>2</span>]. Biotinidase deficiency (BD) is an autosomal recessive disorder. Mild BD refers to the form of the disease with 10%–30% of enzyme activity, and these patients can be asymptomatic until triggered by metabolic stress [<span>2</span>]. We describe a teenager with well-controlled generalized epilepsy who was eventually diagnosed with mild BD.</p><p>This 14-year-old previously healthy girl was diagnosed with idiopathic generalized epilepsy. She had normal development and was noted to be intellectually gifted. She was socially appropriate and participated in competitive cheerleading at school. Her physical examination was normal, including symmetric reflexes in the extremities and a thorough motor and sensory examination. Electroencephalogram indicated generalized, posterior-predominant epileptiform discharges. As part of her epilepsy evaluation, magnetic resonance imaging (MRI) of the brain showed a hyperintense T2-weighted signal in the right cerebral peduncle (Figure 1a) with no abnormal postcontrast enhancement on FLAIR (fluid-attenuated inversion recovery). Whole-exome sequence revealed compound heterozygosity for two pathogenic variants in the <i>BTD</i> gene, confirming a diagnosis of BD.</p><p>Her regimen included levetiracetam 750 mg twice daily and biotin 5 mg daily. MRI brain at 8 months after initial scan showed interval decrease in signal intensity and size of the right cerebral peduncle lesion (Figure 1b). At 20 months after initial imaging, the lesion was barely detectable on imaging (Figure 1c). No further seizure episodes were observed, although the relationship to her epilepsy is unknown. We are currently evaluating when to stop her antiseizure medication.</p><p>This report showcases a rare but treatable cause for epilepsy. The vast majority of BD occurs in the first few months of life and usually before 5 years of age [<span>3</span>]. When the deficiency presents late, it most commonly involves the central nervous system and can mimic acquired neuroinflammatory disorders [<span>2, 3</span>]. In one study, neurological problems occurred in 31% of adult-onset BD and 43% of mild BD, with seizures being one of the most frequent symptoms [<span>2</span>]. While MRI of the brain and spinal cord can be normal, both white matter lesions within the brain and spinal cord have been reported. In one study, the most common imaging abnormalities in children with BD included the optic pathway, fornices, mamillary bodies, hipp","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"324-325"},"PeriodicalIF":0.0,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biljana Horn, Alex Smith, Jennifer Thornton, Tara Symonds, Maureen Roden, Dirk Thye, William P. Whitehouse
Objective
Walking capacity declines prematurely in individuals with ataxia telangiectasia. However, granular data on walking capacity loss in ataxia telangiectasia are scarce. In this large cross-sectional cohort, we describe age-related walking capacity loss reported by participants and compare categories of a subjective walking capacity scale with the International Cooperative Ataxia Rating Scale (ICARS) walking categories.
Methods
Children with ataxia telangiectasia who presented with neurological symptoms at 5 years of age or younger and were 18 years of age or younger at the time of walking capacity reporting were included. Descriptive statistics, Spearman's rank correlations, and simple linear regression of score versus age were used to analyze the data.
Results
Mean walking capacity scores from 372 participants remained stable until age 5, followed by progressive worsening between ages 5 and 14, with persistently high scores thereafter. Categories from the subjective walking capacity scale were mapped to ICARS and its abbreviated, more functional version, Rescored modified ICARS (RmICARS) walking categories. Correlation with age was similar across all three scales (Spearman's rho: 0.711, 0.713, and 0.714). Linear regression in participants aged 5–14 years (N = 220) showed consistent R² values (~0.45) across all scales and confirmed a statistically significant relationship between age and diminished walking capacity (p < 0.001).
Conclusions
Although age-related loss of ambulation was statistically significant, it accounted for just under half of the variability in walking capacity progression. Controlling for disease severity, i.e., classical or the mild variant of ataxia telangiectasia, and capturing more granular data on walking with assistance may improve the prediction of age-associated walking capacity loss.
{"title":"Walking Capacity in Children With Ataxia Telangiectasia From the Global Ataxia Telangiectasia Family Data Platform","authors":"Biljana Horn, Alex Smith, Jennifer Thornton, Tara Symonds, Maureen Roden, Dirk Thye, William P. Whitehouse","doi":"10.1002/cns3.70039","DOIUrl":"https://doi.org/10.1002/cns3.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Walking capacity declines prematurely in individuals with ataxia telangiectasia. However, granular data on walking capacity loss in ataxia telangiectasia are scarce. In this large cross-sectional cohort, we describe age-related walking capacity loss reported by participants and compare categories of a subjective walking capacity scale with the International Cooperative Ataxia Rating Scale (ICARS) walking categories.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Children with ataxia telangiectasia who presented with neurological symptoms at 5 years of age or younger and were 18 years of age or younger at the time of walking capacity reporting were included. Descriptive statistics, Spearman's rank correlations, and simple linear regression of score versus age were used to analyze the data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean walking capacity scores from 372 participants remained stable until age 5, followed by progressive worsening between ages 5 and 14, with persistently high scores thereafter. Categories from the subjective walking capacity scale were mapped to ICARS and its abbreviated, more functional version, Rescored modified ICARS (RmICARS) walking categories. Correlation with age was similar across all three scales (Spearman's rho: 0.711, 0.713, and 0.714). Linear regression in participants aged 5–14 years (<i>N</i> = 220) showed consistent <i>R</i>² values (~0.45) across all scales and confirmed a statistically significant relationship between age and diminished walking capacity (<i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although age-related loss of ambulation was statistically significant, it accounted for just under half of the variability in walking capacity progression. Controlling for disease severity, i.e., classical or the mild variant of ataxia telangiectasia, and capturing more granular data on walking with assistance may improve the prediction of age-associated walking capacity loss.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 4","pages":"299-307"},"PeriodicalIF":0.0,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145761311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号